New combo therapy shows promise for tough lung cancer
NCT ID NCT03667820
First seen Nov 05, 2025 · Last updated May 01, 2026 · Updated 25 times
Summary
This study tests whether adding a precise form of radiation (SABR) to the drug osimertinib can help people with a specific type of advanced lung cancer (EGFR mutant) live longer without their cancer growing. About 41 adults with stage 4 non-small cell lung cancer that cannot be removed by surgery will receive both treatments. The goal is to see if this combination works better than the drug alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.